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Paclitaxel is one of the cancer drugs that often used. These drug kills cancer cells 
by inhibiting mitotic cycle. The efficiency of paclitaxel is increased by the use of 
nanomaterials as a carrier of paclitaxel. Nanomaterials can enhance 
encapsulation efficiency, improve the drug release to the target cell following 
nanomaterial degradation, and improve local accumulation of drug in the cell 
through endocytosis receptor. Nanomaterial that often used forencapsulation of 
paclitaxel is a polymer derived from natural resources such as cellulose. The 
advantages of cellulose as a carrier of paclitaxel are nontoxic, biodegradable, and 
very abundant from various sources. One of the potential sources of cellulose for 
drug delivery system is cassava baggase.  
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I.  INTRODUCTION 
aclitaxel is an effective drug to against cancer, such 
as ovarian breast cancer [1], lung carcinoma, and 
leukemia [2]. Paclitaxel kills the cells by interfering 
mitosis cycle [3]. In the G2 and metaphase, paclitaxel 
prevents microtubule de-polymerization thus disturb 
microtubule equilibrium [1, 4-5]. Nevertheless, 
paclitaxel has a pore water solubility, thereby reduce 
the effectiveness [2]. In addition, the oral 
administration paclitaxel to patients has several 
disadvantages, among a small dosage of drug is 
absorbed, it can be delivered into the liver through 
veins, gastric acid can restructured drug, and very slow 
pharmacokinetic response [6]. 
To improve the pharmacokinetic response of paclitaxel, 
paclitaxel administration to the patient can be 
conducted by paclitaxel-nanomaterial conjugating. The 
conjugation of paclitaxel-nanomaterial can avoid 
kidney filtration and vascular defects thereby increase 
its permeability [17]. Nanomaterial is used as carrier by 
transforming network distribution so-called drug 
delivery systems [2]. Moreover, nanomaterials are 
more easily out of the vessels through endothelial [1]. 
The advantages of nanomaterials are biodegradable, 
biocompatible, nontoxic [3], increase the permeability 
[4], and reduce the side effects [2].  Paclitaxel by dose 
of 30 mg/mm has a good efficiency to overcome 
carcinoma [5]. 
Certain polymers have been used as paclitaxel delivery 
include Poly Vinyl Prolidon-Stearoin Chloride-
Chitosan [7]; PEG-Folic Acid [8]; Chitosan -
oligosaccharides-Au [9]; and Folate -PLA-TPGS [10]. 
Recently, there are no research have reported cellulose 
of cassava baggase as delivery of paclitaxel. 
 
The purpose of this review is to assess the mechanism 
of nanomaterials affect paclitaxel put to death cancer 
including encapsulation efficiency, drug release, cell 
viability, and local accumulation. In addition, this 
review also examines the potential of cellulose as a 
paclitaxel delivery. 
II.  MECHANISM OF PACLITAXEL KILL CANCER 
CELLS 
Paclitaxel has a rigid center ring and flexible side chains 
[11].  Paclitaxel put to death cancer cells by inhibiting 
chromosomes separation on metaphase [12]. This 
inhibition begins from activation of mitotic. Paclitaxel 
is bounded to the N-terminal 31 amino acid β-tubulin 
subunit that disrupts tubulin-microtubule equilibrium 
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[13]. Paclitaxel also attracts several chromosomes that 
are not tied to microtubule spindle through kinetochore. 
As a result, at metaphase, the chromosomes do not have 
symmetrical chromosome lined up the equator, as stem 
cells. Mitotic cycle is pull up at this phase due to the 
next phase, anaphase, have to have symmetric 
chromosome, so generate two symmetric same 
daughter cell as stem cells [14-15] (see fig 1). 
Induction of paclitaxel against cancer cells also causes 
apoptosis; cell fatality is mediated by caspase (one of 
cysteine protease). Morphologically, during apoptosis 
occurs chromatics condensation [9-10]. In the 
leukemia, paclitaxel induce caspase so causes cell death 
in the range of 16-36 hours [16]. The paclitaxel 
structure is presented in Fig. 2. 
 
Figure 1.  Mechanisms of paclitaxel kill cancer cells [14] 
 
Figure 2.  Structure of paclitaxel [11, 16] 
Based on Structure activities relationships OH group at 
C-1 and C-2 benzoloksi are vital groups on anticancer 
activity of paclitaxel. Additionally,the Flexible of C-2 
and C-3 also affect paclitaxel activity. On the other 
hand, the OH group at C-2 is binding site between 
paclitaxel and microtubules. Although C-7 to C-10 do 
not interacted directly, but affects the affinity of P-
glycoprotein [11].  
One of paclitaxel barrier kills cancer cells is multidrug 
resistance (MDR).  P-glycoprotein (Pgp), one of the 
ATP-binding cassettes (ABC), causes resistance 
paclitaxel. These proteins are located at cell membrane 
that has energy of ATP. These energies are used to push 
paclitaxel out of the cell so cannot inhibit mitotic cycle 
[15]. Therefore, nonmaterial is needed as delivery agent 
to reduce resistance of paclitaxel. 
III.  AGENTS 
Cellulose is very potential on the drug encapsulation, 
one of which paclitaxel. One of mean used on 
encapsulation of paclitaxel is conjugation polymer with 
paclitaxel. Chain side of the polymer is interacted with 
the existing paclitaxel so it will be trapped in the 
polymer (see fig 3) [17].  
 
There are several advantages of cellulose as delivery 
agent. First, cellulose has a good biocompatibility, 
meaning that the much number of hydroxyl groups, it 
interacts easily with other molecules, chemically or by 
hydrogen bonds. Secondly, cellulose is nontoxic so it is 
safe for humans. Third, the long carbon chains cause 
cellulose hydrophobic that prevent drug degradation 
during delivery. Fourth, cellulose is biodegradable, 
when it reach cell, it rupture easily caused by cell 
environment so the drug more easily released by 
following cellulose degradation [18]. The use of 
cellulose for encapsulation of ACN increase release 
rate. Within 24 hours, more than 90% of the drugs are 
released toward target cells. This suggests that cellulose 
degradation is very easy to increase drug release rate 
[19]. Additionally, cellulose also has good thermal 
stability. Microcrystalline cellulose is depredated at 
temperatures of 296-344oC. This means that the 
cellulose resistant to temperature changes. During 
encapsulation process, there is no cellulose degraded so 




Figure 3.  Paclitaxel encapsulation scheme [17] 
From terms of resources, cellulose has highly abundant 
availability. Cellulose can be obtained from nature 
resources, for example from waste wood and biomass 
(bagasse sugarcane, oil palm empty fruit bunches, and 
cassava) [18]. Availability of cellulose derived from 
cassava baggase is one distinct advantage. Cassava 
products in Indonesia at 2013 reached 23,936,921 tons 
[21]. It is predicted cassava products in Indonesia will 
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increase continuously to supply the needs of starch in 
Indonesia. The increase of cassava production will 
increase the amount of cassava baggase product. 
Cellulose content in cassava is the second greatest after 
the starch, namely 34% [22]. Unfortunately, until now 
there is no study that reported the use of cellulose from 
cassava baggase as encapsulation materials of 
paclitaxel. 
IV.  EFFECT OF NANOMATERIAL ON 
CYTOTOXICITY PASLITALSEL 
A. Improvement of Encapsulation Efficiency 
Surfactant is used for the synthesis of nanomaterials to 
improve encapsulation efficiency of paclitaxel. [23]. 
surfactant stabilizes paclitaxel in nanomaterial thus 
inhibiting drug disintegration from nanomaterial during 
delivery process. Vitamin E as surfactant of paclitaxel, 
approximately 81.6% paclitaxel remain in 
nanomaterials for delivery process to the target cell. 
Whereas, in the absence of vitamin E amount paclitaxel 
that reaches the target cells only about 71.7% [24]. 
Meanwhile, the encapsulation efficiency value of 
paclitaxel in nano-Poly Vinyl Chloride Prolidon-
Stearoin-Chitosan was about 92.8% [7]. On the other 
hand, paclitaxel which remain in nano-PEG-folic acid 
during delivery process is by 13.1%. The low 
encapsulation efficiency is due to repolymerization 
reaction of PEG-nanomaterial [8]. In addition, 
paclitaxel solubility in water increases with increasing 
surfactant concentration which increase the diffusion 
paclitaxel of the nanomaterial heading out during 
delivery process [3]  
B. Drug Release Rate 
Nanomaterial is used for encapsulation paclitaxel to 
speed up the release of the drug brush [25]. Within the 
duration of 24 hours, at pH of 5.6 about 11.2% from 
13.1% paclitaxel that was delivered by nano-PEG-folic 
acid has reached the target cell. Paclitaxel nonspecific 
bonding in nano-PEG-folic acid a network significantly 
increase release rate [8]. On the other hand, the high 
release rates paclitaxel in nano-PEG-Cyclodextrin 
occurs in 6-12 hours, where about 60% paclitaxel been 
released. PEG result nanomaterial that has more 
slippery surface to facilitate penetration through the 
mucous lining in gut [25-26]. Additionally, paclitaxel 
encapsulated chitosan-oligosaccharides nano-Au 
released to target cells after three hours. After 48 hours 
approximately 96% of paclitaxel has released from 
nanomaterial [3,9] (see Fig 4). 
 
 
Figure 4.  (a).  Paclitaxel in nanomaterial, (b) cancer cells, 
(c) paclitaxel has entered into cancer cell, (d) degradation 
paclitaxel follows nanomaterial degradation [3,9] 
High drug burst rate in the first day caused by several 
mechanisms, first, diffusion through a channel formed 
during nanomaterial preparation. Second, drug release 
followed the nanomaterial degradation. The strong 
explosion is caused by local diffusion of paclitaxel 
which is entrapped weakly in polymer matrix. Terminal 
carboxylic acid increases release rate. The functional 
groups accelerate water absorption so accelerate 
swelling and degradation of nanomaterial. Small 
molecular weight also improves nanomaterials 
degradation because of low hydrophobic that facilitates 
pores formation [3]. It showed continuously paclitaxel 
release rates after 24 hours. After 48 hours paclitaxel 
that is released from nano-PEG-Chitosan-Transferin 
about to 67.14% and 69.64% at pH 7.4 and 4.0. 
Continuous release is resulted from paclitaxel diffusion 
through polymer pores as polymer degradation [26]. 
Third, the small particles have a large surface so 
produce high brush in a short time [3]. Additionally, 
paclitaxel which was released by nano-chitosan-
oligosaccharides-Au to target cells by 96%, 68%, and 
56% at pH 5.5; 6.8; and 7.4. This means that drug brush 
of nanomaterial more easily under acidic conditions [9]. 
The environmental of cancer cells have an acidic 
condition. Endosome has pH of 5-6, while lysosomes 
have pH of 4-5. The positive charge of nanomaterial 
will be exchanged with protons in acidic media. 
Consequently, nanomaterial less stable and easily 
degraded under acidic and drugs were released from the 
nanomaterial to target cells. Therefore, drug release was 
better under acidic than neutral or alkaline condition 
[27]. 
C. Cell Viability 
Nanomaterial significantly decreased cell viability [3]. 
This is due to the positive charge of the nanomaterial. 
The positive charge of nanomaterials cause cellular 
interactions with negative charged of plasma membrane 
stronger than the negative charge [26,28]. Pure 
paclitaxel with a concentration of 0.28 ug / ml reduce 
cell viability CT26-CEA; while paclitaxel was released 
by nano-polyelectrolyte-PEG reduce cell viability 
CT26-CEA at a concentration of 0.014 µg / ml. This 
indicates that the nano-encapsulation paclitaxel-PEG 
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polyelectrolyte decreased the cell viability significantly 
by proliferative activities [28].  
Moreover, nanomaterials also increase cell death in 
tumor tissue by generating hyperthermia [5] and change 
cell morphology [9,28]. Nano-Folate-Paclitaxel-PLA-
TPGS with concentration of 3 mg / ml can damage 
HeLa cells. This means that the encapsulation paclitaxel 
in nanomaterial effectively destroy target cells by 
increasing cell internalization. Folic acid damage target 
cells that are internalized by the cell-folate receptor 
endocytosis [10]. Paclitaxel encapsulated by nano-
PEG-folic acid with a concentration of 4.9 nM provide 
a 50% growth inhibition of MDA-MB231 cells 
[8,23,27]. The nanomaterials penetrate cells 
exclusively through receptor endocytosis. When 
gamma carbonyl of folic acid bound to the PEG, FR 
binding affinity cannot be measured accurately and 
absorption messages by receptor endocytosis via 
receptor endocytosis cannot be detained.  
D. Local accumulation Paclitaxel in Cells  
In vivo, after 24 hours paclitaxel accumulation in the 
tumor tissue of mice was higher than in other peritoneal 
tissue [29]. Effectiveness paclitaxel local accumulation 
in cells [23] occur through several mechanisms, the 
first, increase in permeability. Second, is effect of 
retention [7, 10]. Third, is redistribution of drug from 
the peritoneal cavity through the circulatory system. 
Fourth, is drug diffusion through liquid which was 
collected in the tumor tissue [29]. After seven days of 
Nano-Folate-Paclitaxel-PLA-TPGS more effectively 
inhibit tumor tissue than pure paclitaxel [10]. Certain 
compounds such as tetrandrin (TET) can also weaken 
Pgp functions in cell membrane, making it easier entry 
into cells. TET with a concentration of 5 μM affects the 
cytotoxicity of MCF-7 and MCF-7 / ADR [27].  Tumor 
inhibition ratio values of nano-Poly Vinyl Chloride 
Prolidon-Stearoin-Chitosan-Paclitaxel about to 76.1% 
while the tumor inhibition ratio value of pure paclitaxel 
about to 52.9%. It is attesting that nano-Poly Vinyl 
Chloride Prolidon-Stearoin-Chitosan-Paclitaxel inhibit 
tumor cells more effective in mice than pure paclitaxel 
[7]. In cancer cells, nanomaterials maintain therapeutic 
concentrations so reduce reactivity of phase G2 and M 
that is radiosensitive phase in mitotic cycle [2,5]. 
Paclitaxel concentration survives in cancer cells for 48 
hours by using nano-PEG-cyclodextrin as a carrier. 
This is due to increased residence time of a 
nanomaterial that is close to the absorption, as 
presented on Fig. 5 [29-30]. 
Nowadays, research topic that is study by researchers in 
various countries is a nanomaterial. This is due to the 
nanomaterial has physical and chemical properties are 
uniquely different with the amount of material. The 
properties include the volume ratio and high surface, 
high reactivity, and high electron conductivity. Some of 
scopes that have use nanomaterials are including 
electronics, biomedical, pharmaceutical, photography, 
and the energy [29-30]. 
 
 
Figure 5.  Paclitaxel accumulation in the tissues (a) without 
nanomaterial, (b) with nanomaterial [29-30] 
V.  CONCLUSION 
Oral administration paclitaxel to the patient is less 
effective because degraded easily during delivery. On 
the other hand, the encapsulation of paclitaxel can 
improve the effectiveness of the drug. Nanomaterial 
increase the drug explosion rate followed nanomaterial 
degradation and through the process of diffusion. High 
release rates occurred in the first day. Moreover, 
nanomaterials also significantly decrease cell viability 
through changes in cell morphology. Local 
Accumulation paclitaxel in tumor cells also increase by 
using nanomaterial as delivery agent of paclitaxel. One 
of nanomaterials that are used for encapsulation of 
paclitaxel is cellulose as easily degraded, non-toxic, and 
the abundant availability materials from various 
resources. The authors suggest research encapsulation 
of paclitaxel using cellulose derived from cassava 
baggase. 
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